Clinical Trial of Auceliciclib in patients with advanced solid tumours
Phase 1, Multi-Site, Australia, (Protocol: AU08-001-01)
Lead Site: SOCRU, Bedford Park, SA, Australia
Lead Principal Investigator: Dr Ganessan Kichenadasse, MD, PhD, FRACP (clinicaltrials@socru.org.au)
Medical Monitor: Dr Paul Wabnitz, MD, PhD, MBA, FRACP (paul.wabnitz@clinPHARMA.com.au)
Sponsor: Aucentra Therapeutics
Status: Actively recruiting Phase 1a
Active Sites: Southern Oncology Clinical Research Unit (SOCRU), Bedford Park, South Australia
A Phase 1a/b, open-label, dose-exploration, combination/expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with Temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).
For more information, this Trial is registered on the Australian New Zealand Clinical Trials Registry (ANZCTR). Additional detailed information can be found by the following links:
https://www.anzctr.org.au/ACTRN12621000479808.aspx
Patients can register their interest directly with the lead site Southern Oncology Clinical Research (SOCRU) Unit at Bedford Park, South Australia clinicaltrials@socru.org.au. It is preferable to have your treating Doctor (Oncologist or Primary Care Physician) provide a referral letter addressed to the Principal Investigator Dr Ganessan Kichenadasse (clinicaltrials@socru.org.au).
We will provide further updates as the trial progresses.
Last updated: April 2021